Implantation and Placental Development Research Group
Research Group Head
Our group is studying the molecular mechanisms governing the fundamental cell biology during uterine remodelling for embryo implantation. This work has direct translational relevance, particularly for patients with uterine infertility and implantation failure in IVF treatment. Conversely, preventing uterine preparation for implantation is an attractive strategy for non-hormonal contraception. Furthermore, many uterine remodelling aspects of implantation are shared in cancer progression.
We aim to improve maternal and fetal health outcomes through improved understanding and management of placental development and pregnancy diseases such as pre-eclampsia, intrauterine growth, and miscarriage. We are particularly interested in a group of serine proteases, the HtrA protease family, in placental development and pregnancy diseases. One of our major goals is to develop strategies for early detection and treatment of pre-eclampsia, a life-threatening disorder of human pregnancy. In addition, we are interested in the long-term health consequences of placental insufficiency and pregnancy diseases.
We utilise a number of strategies including molecular biology, biochemistry, cell culture, gene knockdown cell and knockout mouse models, and proteomics. We collaborate closely with specialist clinicians, and a particular emphasis of our research is to translate our basic research discoveries into clinically useful practices.
- Endometrial Receptivity for Embryo Implantation, Uterine Infertility, and IVF Improvement
- Placental Development, Pregnancy Disorders, and Long-term Health Consequences of Placental Insufficiency
- Women-centred non-hormonal contraception
- Non-invasive endometrial cancer diagnosis
Chen Q, Wang Y, Zhao M, Hyett J, Costa FS, Nie G (2016). Serum levels of GDF15 are reduced in preeclampsia and the reduction is more profound in late-onset than early-onset cases. Cytokine 2016 May 9;83:226-230.
Heng S, Vollenhoven B, Rombauts LJ and Nie G (2015). A High-Throughput Assay for the Detection of α-Dystroglycan N-Terminus in Human Uterine Fluid to Determine Uterine Receptivity. J Biomol Screen. 2016 Apr;21(4):408-13.
Heng S, Paule SG, Li Y, Rombauts LJ, Vollenhoven B, Salamonsen LA and Nie G (2015). Post-translational removal of alpha-dystroglycan N-terminus by PC5/6 cleavage is important for uterine preparation for embryo implantation in women FASEB 29, 4011-4022.
Teoh SS, Zhao M, Wang Y, Chen Q and Nie G (2015). Serum HtrA1 is differentially regulated between early-onset and late-onset preeclampsia. Placenta 36:990-995.
Singh H, Zhao M, Chen Qi, Wang Y, Li Y, Kaitu’u-Lino TJ, Tong S and Nie G (2015). Human HtrA4 expression is restricted to the placenta, is significantly up-regulated in early-onset preeclampsia, and high levels of HtrA4 cause endothelial dysfunction. JCEM 100, E936-E945.
Paule S, Nebl T, Webb AL, Vollenhoven B, Rombauts LJF and Nie G (2015). Proprotein convertase 5/6 cleaves platelet derived growth factor A in the human endometrium in preparation for embryo implantation. Mol Hum Reprod 21, 262-270.
Heng S, DynonK,Li Y, Edgell T, Rombauts LJ; Vollenhoven B and Nie G (2015). Development of a high throughput assay for human proprotein convertase 5/6 for detecting uterine receptivity. Anal Biochem 475, 14-21.
Singh H, Nero TL, Wang Y, Parker MW and Nie G (2014). Activity-modulating monoclonal antibodies to the human serine protease HtrA3 provide novel insights into regulating HtrA proteolytic activities. PLoS ONE 7(9), e45956.
Ho H, Li Y and Nie G (2014). Inhibition of embryo implantation in mice through vaginal administration of a proprotein convertase 6 inhibitor. Reproductive Biology 14, 155-159.
Singh H, Li Y, Fuller PJ, Harrison C, Rao J, Stephens AN and Nie G (2013). HtrA3 is downregulated in cancer cell lines and significantly reduced in primary serous and granulosa cell ovarian tumors. J Cancer 4,152-164.